Biogen, Cambridge MA | Nearby Businesses

• Biotechnology
• Community and Government
• Fitness Center
• Gas and Chemical Service
• Sports and Recreation

250 Binney St
Cambridge, MA 02142
(617) 679-2000

The Koch Institute grows out of and transcends the MIT Center for Cancer Research (CCR), which was founded in 1974 by Nobel Laureate and MIT Professor Salvador Luria. It is one of eight National Cancer Institute-designated basic (non-clinical) research centers in the U.S. Our mission is to apply the tools of science and technology to understand how cancer is caused, progresses and responds to treatment. We bring together scientists and engineers to discover how the disease behaves at a molecular level and to work on solving real cancer-related problems. The Koch Institute is both a physical entity and an organizing body for MIT's cancer research community at large (over 600 researchers across the Institute). It grows out of MIT's proven strengths in molecular biology, genetics, cell biology and immunology and stimulates extensive collaboration. The Koch Institute and its extramural partners comprise nearly 50 member laboratories from 7 departments.

Since 1999, the ALS Therapy Development Institute has been dedicated to research. Developed by a family member whose brother had ALS, the emphasis has been to work closely with patients and their families to raise valuable funds to help slow down and eventually cure ALS.

WHAT IS LABCENTRAL? A 28,000 square-foot facility in the heart of the Kendall Square, Cambridge, biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 25 startups comprising approximately 100 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation. The first startups joined us in early November, with lab operations launching officially November 15, 2013. A Better Way for Life-Sciences Startups There has never been a shortage of groundbreaking science in Massachusetts, nor of talented people with entrepreneurial spirit and vision. What was lacking ‒ affordable, move-in-ready laboratory facilities suitable for early-stage research. LabCentral fills this gap. To paraphrase Doug Crawford, the executive director of LabCentral affiliate QB3/UCSF: Once biotech entrepreneurs are convinced that they should try to bring their work to market, either with or without bridging-the-gap funding, they are often astounded by the next mental adjustment: the amount of effort required to turn their attractive innovation into a useful product. Besides securing intellectual property and developing a business plan, the budding entrepreneur must find a location for the new company – ideally with low rent, important equipment provided, access to supporting services and other needed resources. [K. D. Harrison, N. S. Kadaba, R. B. Kelly, D. Crawford, Building a life sciences innovation ecosystem. Sci. Transl. Med. 4, 157fs37 (2012).] Successful co-working facilities have been built for aspiring IT companies in many centers of innovation, but there has been a paucity of laboratory spaces for biotech. Laboratory infrastructure is costly, and the initial investment is much larger than just a desk and a good broadband connection. Lease, fit-out, and permitting of lab space consumes precious resources ‒ both human and capital ‒ that could be better spend fine-tuning technology to prepare for clinical trials or commercialization. LabCentral solves this problem by adopting very conscious design choices to optimize use of available space, and to facilitate shared use of resources, equipment, and infrastructure. We combine this with a goal-oriented understanding of “concierge” services that remove many operational burdens from startup companies.

Moderna Therapeutics is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.

The Department of Biological Engineering was founded in 1998 as a new MIT academic unit, with the mission of defining and establishing a new discipline fusing molecular life sciences with engineering. The goal of this biological engineering discipline is to advance fundamental understanding of how biological systems operate and to develop effective biology-based technologies for applications across a wide spectrum of societal needs including breakthroughs in diagnosis, treatment, and prevention of disease, in design of novel materials, devices, and processes, and in enhancing environmental health. Our departmental epigram is 'Creating Biological Technologies, from Discovery to Design', designating our intertwined emphases on advances in basic bioscience and in applied biotechnology. The innovative educational programs created by BE reflect this emphasis on integrating molecular and cellular biosciences with a quantitative, systems-oriented engineering analysis and synthesis approach, offering opportunities at the undergraduate level for the SB in Biological Engineering and at the graduate level for the PhD in either Applied Biosciences or Bioengineering. BE also partners with the departments of Biology and Electrical Engineering & Computer Science to jointly offer a PhD in Computational & Systems Biology, and with the departments of Biology and Civil & Environmental Engineering to jointly offer a PhD in Microbiology. Research opportunities for BE undergraduate students, graduate students, and postdoctoral associates abound across an exciting landscape of interdisciplinary laboratories, centers, and initiatives, including the Center for Biomedical Engineering, the Center for Environmental Health Sciences, the Center for Emergent Behavior of Integrative Cellular Systems, the Center for Gynepathology Research, the Synthetic Biology Center, and the Division of Comparative Medicine. Graduate students in the BE PhD programs can participate in the NIGMS Biotechnology Training Program, the NIEHS Toxicology Training Program, and the NIBIB Biomechanics Training Program. More than one-third of the MIT BE faculty hold membership in one or more of the major US academies, including 6 in the National Academy of Engineering, 5 in the National Academy of Science, 7 in the Institute of Medicine, and 6 in the American Academy of Arts & Sciences. BE is one of four bioengineering programs (along with UCSD, Berkeley/UCSF, and Caltech) assigned #1 rankings in the current National Research Council report, and ranks #1 among bioengineering departments in citations per publication in a recent Academic Analytics study. Numerous biotechnology companies have been generated by BE faculty and students, in the Cambridge/Boston area and further nationwide.

We realized that small team research needs more than just space, but a platform to accelerate performance. Success requires flexible facilities, dynamic operations, and industry leading expertise on hand. We built this platform at the intersection of the world’s leading life science companies, VCs and academic institutions in the heart of Kendall Square. The whole is much larger than the sum of our partnerships and resources.

NeoBioLab is headquartered in the center of a biopharmaceutical zone located in Cambridge, Massachusetts. We are a dedicated biology service provider and partner, providing innovative solutions to molecular and cellular biology, in vivo experiments and drug screening services. NeoBioLab routinely works with pharmaceutical and biotechnological companies and academic institutions of all sizes, advancing their research efficiency and core competitiveness and ultimately improving their research productivity. NeoBioLab guarantees the quality of its products and services through multiple layers of quality control management. In addition, we seek strategic collaborators and integrate various resources so that we can maximize our talents in the discovery and development of medicines and therapies. NeoBioLab’s mission is to provide innovative solutions and accelerate the healthcare R&D.

Developing novel medicines through scientific innovation to better patients' lives.

Discover and interpret variants with flexible, open-source pipelines and our scalable computation engine. Collaborate across your research network, privately share results, and draw from existing datasets.

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrodic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.

XRpro Sciences, Inc. provides high-value services -- from assay development and high throughput screening through data analysis -- for ion channels and transporters using its proprietary, lablel-free XRpro® technology. XRpro® technology, based on X-ray fluorescence, is a novel method that enables high throughput assessment of ion channels and transporters including challenging assays that are difficult or impossible to conduct using other technologies. XRpro Sciences is dedicated to solving the challenges scientists face by bringing the value of XRpro® technology to their ion channel and transporter research and drug development activities. Our services combine the expertise and capabilities of our scientific team with a collaborative environment to provide new scientific insights and promote development of quality drug candidates. Advantages of XRpro® Technology: - Label-free - No dyes or radiolabels - Works in complex matrices - Serum, high DMSO, opaque solutions - Broad range of targets - ion channels, transporters, and other challenging targets - Straightforward assay implementation - uses standard cell biology, microplates, automation, and assay procedures